Spesolimab is a monoclonal antibody that targets interleukin-36 receptor (IL-36R). Spesolimab has been approved for the treatment of generalized pustular psoriasis (GPP) flares in adults.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.